← All peptidesDelivery format
Oral peptides
Peptides in pill or capsule form
Oral peptide delivery has been the holy grail of peptide therapy for decades. Most peptides degrade in stomach acid before reaching the bloodstream — but the 2026 generation of oral formulations changes the math. Salt-form modifications (BPC-157 arginate), small-molecule analogs (orforglipron), and SNAC-carrier technologies (Rybelsus) all crack the bioavailability problem in different ways. This is the comprehensive index of every peptide we cover that ships in oral form, ranked by current search demand.
8 peptides we cover in this format
Ranked by 30-day query volume
Orforglipron
+92%Eli Lilly's first non-peptide oral GLP-1 receptor agonist. Small-molecule structure means no SNAC carrier required, no food-timing restrictions (unlike Rybelsus), and no injection. Phase 3 ATTAIN-1 read-out April 2026 showed ~14.7% mean weight loss at 72 weeks. PDUFA date pending.
Metabolic375K/moResearch onlySemaglutide
+8%GLP-1 receptor agonist (Wegovy, Ozempic, Rybelsus). FDA-approved for type 2 diabetes, chronic weight management, and cardiovascular risk reduction in obesity. STEP-1 mean weight loss 14.9% at 68 weeks; SELECT 20% MACE reduction in adults without diabetes.
MetabolicWeight Loss pillar201K/moFDA approvedTirzepatide
+61%The first dual GIP/GLP-1 receptor agonist. Eli Lilly's tirzepatide produced superior weight loss to semaglutide in the head-to-head SURMOUNT-5 trial (20.2% vs 13.7%), making it the most effective peptide weight-loss drug currently approved.
MetabolicWeight Loss pillar98.4K/moFDA approvedBPC-157
+42%Pentadecapeptide derived from a human gastric-juice protein, extensively studied in rodent models for tendon, ligament, and gut-tissue healing via angiogenesis and fibroblast-migration mechanisms. Human evidence base remains thin. FDA Interim Category 2 pending July 2026 PCAC review.
RecoveryRecovery pillar48.2K/moCat 2 → reviewWADA prohibited5-Amino-1MQ
+24%Small-molecule NNMT inhibitor (nicotinamide N-methyltransferase). Animal-model data shows fat-loss + metabolic-regulation effects via SAM-cycle and NAD+ modulation. Minimal human data. Research compound, not a peptide — included for the platform's metabolic-research scope.
Longevity28K/moResearch onlyDihexa
+41%Hepatocyte growth factor (HGF) mimetic and angiotensin IV analog. Animal data shows ~7 orders of magnitude greater synaptogenic potency than BDNF. Crosses BBB. Research-only. Concern: HGF mimetics carry theoretical oncogenic risk — nasal route may localize exposure better than oral.
Cognitive24K/moResearch onlyTesofensine
+19%Triple monoamine reuptake inhibitor (DA, NE, 5-HT) originally developed for Alzheimer's. Phase 3 trials show ~10% weight loss — comparable to early GLP-1 era results. Approved in Mexico (2023) as a non-peptide weight-loss drug; FDA application stalled over CV safety concerns.
Metabolic22K/moResearch onlyKPV
+18%C-terminal α-MSH tripeptide (Lys-Pro-Val) with documented mast-cell-stabilizing and NF-κB-inhibiting activity. Phase 2 evidence in ulcerative colitis; off-label use in MCAS, IBS, and inflammatory skin protocols. Oral bioavailable via the PepT1 transporter.
InflammationImmune & Gut pillar6.7K/moResearch only
New to peptides?
Read the medical-reviewer-signed primer that explains how peptide therapy actually works — what the evidence says, what it doesn't, and how to read the regulatory landscape.
Read: What are peptides?